Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.200
-0.030 (-2.44%)
At close: Dec 5, 2025, 4:00 PM EST
1.210
+0.010 (0.83%)
After-hours: Dec 5, 2025, 5:01 PM EST
Coherus Oncology Revenue
Coherus Oncology had revenue of $11.57M in the quarter ending September 30, 2025, with 91.19% growth. This brings the company's revenue in the last twelve months to $277.73M, up 152.07% year-over-year. In the year 2024, Coherus Oncology had annual revenue of $266.96M with 3.78% growth.
Revenue (ttm)
$277.73M
Revenue Growth
+152.07%
P/S Ratio
0.50
Revenue / Employee
$1,218,105
Employees
228
Market Cap
145.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 266.96M | 9.72M | 3.78% |
| Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
| Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
| Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
| Dec 31, 2020 | 475.82M | 119.75M | 33.63% |
| Dec 31, 2019 | 356.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 1.56M | -188.55M | -99.18% |
| Dec 31, 2016 | 190.11M | 160.07M | 532.82% |
| Dec 31, 2015 | 30.04M | -1.07M | -3.42% |
| Dec 31, 2014 | 31.11M | 28.36M | 1,030.72% |
| Dec 31, 2013 | 2.75M | 852.00K | 44.87% |
| Dec 31, 2012 | 1.90M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CHRS News
- 26 days ago - Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody - GlobeNewsWire
- 4 weeks ago - Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer - GlobeNewsWire
- 5 weeks ago - Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 6 weeks ago - Coherus Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga